Ganeden has used its patented probiotic strain to develop an immune health ingredient: Staimune. Ganeden received FDA GRAS on the new ingredient, which utilizes the cells of the probiotic GanedenBC30® to support immune health, at cost effective inclusion levels. Available in late summer 2017, Ganeden anticipates Staimune to be an industry-changing development.
Officially identified as “Inactivated Bacillus coagulans GBI-30, 6086”, Staimune’s ease of formulation opens up new opportunities in functional foods and beverages—most importantly in shelf-stable beverages and high-water-activity products. Staimune is FDA GRAS, non-GMO, organic compliant and kosher, making it accessible for use in a vast amount of applications.
Multiple peer-reviewed and published studies show the immune health benefits of GanedenBC30 cells, with additional in-vitro and human clinical studies on Staimune currently underway.
Staimune provides opportunities for manufacturers that want to focus specifically on immune health, and for those with processes that cause formulation challenges for live probiotics. With an inclusion rate of just 50mg, Staimune does not alter the flavor or texture profiles of finished goods, allowing for easy application into a large number of product categories.
Ganeden’s probiotic research and product development includes an extensive library of published studies and more than 135 patents for probiotic technologies in the supplement, food, beverage, animal health, sports nutrition and personal care ingredients markets. Staimune will be available for formulation in summer 2017.